Exero Medical Appoints Prominent Gastrointestinal Expert Professor Charles Knowles to its Scientific Advisory Board

Exero Medical Appoints Prominent Gastrointestinal Expert Professor Charles Knowles to its Scientific Advisory Board

OR YEHUDA, Israel – March 10, 2020Exero Medical, developer of a biodegradable wireless sensor for early detection of anastomotic leaks (AL) following GI surgery, today announced the appointment of Charles Knowles, Professor of Surgery at Queen Mary University of London and Consultant Colorectal Surgeon at Barts Health NHS Trust, to its scientific advisory board.

“We are excited to welcome Professor Knowles, whose clinical expertise and deep knowledge of the gastrointestinal field brings immediate value to Exero Medical, and will be instrumental in navigating both clinical trials and clinical implementation of our AL detection technology,” said Erez Shor, PhD, CEO of Exero Medical. “Professor Knowles provides us with an axis between the operation and functionality of our leak detection system and its clinical application. His expert input will be vital in the development of our technology, which will result in better, safer care of GI surgery patients.”

Professor Knowles has been a major contributor to the field of gastrointestinal research for over 25 years. Professor Knowles is Deputy Director of the Blizard Institute and Honorary Professor of Experimental Therapeutics at UCL. He is Chair of several research committees including the European Society of Coloproctology. Professor Knowles has authored over 190 peer reviewed publications as well as contributed several book chapters to major international colorectal and general surgical texts.

“AL has a 6-10% occurrence rate post-operation in lower GI procedures and can lead to life threatening complications, with substantial risk of mortality,” said Professor Knowles. “I look forward to working closely with the Exero Medical team, whose technology is novel to this field, to address this widespread issue and help alert physicians to post-operative AL early on, allowing for timely medical intervention and improved patient outcomes.”


About Exero Medical

Exero Medical saves lives through early detection of anastomotic leaks following gastrointestinal (GI) surgeries, addressing a $2 billion market with its patented sensor technology. The company has created a patent-pending implantable biodegradable wireless sensor designed to continuously monitor the GI tract near the surgical site, alerting physicians to potential anastomotic leakage post-operation. Driven by an adaptive machine learning engine, Exero’s sensors are trained to detect patient deterioration during the recovery period, and also enable early patient discharge by identifying healthy tissue healing. Operating under MEDX Xelerator, Exero Medical is backed by Boston Scientific, MEDX Ventures and Intellectual Ventures.

For more information, visit

Follow Exero Medical on LinkedIn and Twitter.


This website uses cookies

We use cookies to enhance your experience on our site. Visit our Privacy Policy and Terms and Conditions of Use to learn more. By using our site, you agree to our use of cookies.

Agree | Learn More
Subscribe to Newsletter